To construct a cyclin-luciferase fusion protein (pSP cyc-luc), the N-terminal sequence of Xenopus laevis cyclin B1, including amino acids 2-97, was amplified by PCR, digested with BstEII, and ligated into the pSP-lucNF expression vector (Promega).
supplemented with 1 mg/ml bovine ubiquitin (Sigma) unless otherwise stated. Cyc-luc expressed in reticulocyte lysate was diluted 1/200 for most assays. High-throughput screening utilized the bacterially expressed and purified cyclin-luc fusion protein, which was added to extracts at a final concentration of 0.1 µg/ml. To induce entrance into mitosis, cyclin B∆90 protein was added to a final concentration of 10 µg/ml. For the dose response analysis (Fig. S2 ), inhibitors were purchased from Calbiochem (San Diego, CA) and dissolved in DMSO as 10 mM stocks. Cyclin-luciferase and cyclin B∆90 were mixed with interphase extract and placed on ice. Inhibitors were then added to extracts to yield a final DMSO concentration of 1%. 10 µl aliquots of extract were distributed into 384-well white Cliniplates (Labsystems), and cell cycle progression was initiated by warming the samples to room temperature. After 60 minutes, 30 µl of luciferin reagent (20 mM Tricine pH 7.8, 470 µM D-Luciferin [Molecular Probes]), 270 µM Coenzyme A, 0.1 mM EDTA, 33 mM DTT, and 530 µM ATP) was added using a multidrop dispenser (Labsystems). Luminescence was measured on an Analyst plate reader (LJL Biosystems).
The values for 3 replicates were averaged. For the dose response analysis (Fig S2) , percent inhibition was calculated as 100*(T-M)/(I-M) where T equals the test value for the inhibitor, M equals the value in a mitotic extract lacking inhibitor, and I equals the value in an interphase extract. For the experiment in Fig. S1 , methylated ubiquitin was added to interphase extracts at a concentration of 1 mg/ml in the presence or absence of added unmodified ubiquitin (1 mg/ml) used as competitor. Cyclin-luciferase and cyclin B delta 90 were then added. After 60 minutes, the reactions were stopped and analyzed as described above.
Chemical Libraries and Chemical Characterization of Active Compounds
Compound collections screened included 16,320 compounds from Chembridge Corporation (San Diego, CA; Diverset E); 1991 compounds from the NCI Diversity set, 
High-throughput screening
Chilled interphase Xenopus extracts containing cyclin B ∆90 and cyclin-luciferase were spread onto chilled custom-designed 1536-well plates (S5) that held 2 microliters of extract per well. 100 nl of compound (5-10 mM in DMSO) was then transferred into the assay plate using a custom-designed pin-transfer robot (S5) . After a 60 minute incubation at room temperature, a PixSys 3200 dispenser (Cartesian Technologies, Irvine, CA) was used to dispense 200 nl of a 10x concentrated luciferin solution to each well of the assay plate. Immediately after filling, the plate was imaged using the Leadseeker system (Amersham Pharmacia Biotech, Amersham, U.K. Table S1 provides the relevant Chembridge ID or NCI identification numbers for each of these compounds. Structures of these compounds will also be accessible on the Chembank web site upon publication (http://chembank.med.harvard.edu/).
Retesting of Active Compounds
Dry compounds were redissolved at 20 mM concentration in DMSO, or at 10 mM in a 50:50 water:DMSO mixture (for C10 and C92). These compounds were then diluted ten-fold in XB and mixed thoroughly. To retest compounds under conditions of the original screen, in which compounds were added prior to mitotic entry, chilled interphase extract was mixed with cyclin B ∆90 (10 µg/ml) and cyc-luc (0.1 µg/ml) in bulk and then 27 µl of extract was pipetted to each well of a chilled 384-well plate. Three microliters of each compound (diluted in XB) was then added to each well, and then compounds mixed thoroughly, yielding a final concentration of 200 µM (100 µM for C10 and C92). Plates were warmed to room temperature. After 70 minutes, 5 µl aliquots were transferred to another plate, and then 30 µl of luciferin reagent was added to each well and luminescence measured. Percent inhibition was calculated as described above. The reported values represent the average of three independent measurements. To determine whether compounds lost inhibitory activity when added after mitotic entry, interphase extracts were treated with 10 µg/cyclin B ∆90 for 50 minutes at room temperature to drive entry into mitosis and then chilled on ice. Cyc-luc was then added, and then 27 µl of extract was pipetted to each well of a chilled 384-well plate. Three microliters of each compound (diluted in XB) was then added to each well, and then compounds mixed thoroughly. Plates were warmed to room temperature. After 60 minutes, 5 µl aliquots were transferred to another plate, and then 30 µl of luciferin reagent was added to each well and luminescence measured. To determine whether compounds inhibited Cdh1-induced proteolysis, recombinant Cdh1 (0.1 µg/ml) and cyc-luc were added to chilled interphase extracts. Extracts were then pipetted and compounds added as above. Plates were warmed to room temperature and incubated for three hours, following which luminescence was measured as above. To determine whether compounds inhibited degradation of a β-catenin reporter protein, chilled interphase extracts received recombinant Axin and beta-catenin-luciferase reporter as described (S6) . Extracts were aliquoted to chilled plates and compounds distributed as described above. Plates were warmed to room temperature, incubated for three hours, and luminescence measured. In all assays, percent inhibition was calculated as 100*(T-A)/(I-A) where T equals the test value for the inhibitor, I equals the value for inactive interphase extracts lacking either cyclin B ∆90, Cdh1, or Axin protein, and A equals the value for an extract that lacks a chemical inhibitor but is stimulated to degrade the reporter protein by addition of cyclin B ∆90, Cdh1, or Axin protein. In the case of Cdh1 addition, we noted that many of the Class I compounds led to stimulation of proteolysis under these conditions ( we believe that these compounds stimulate Cdh1-dependent degradation by inhibiting an unidentified kinase in interphase Xenopus extracts.
Preparation of UbSic1
Sic1, expressed in E. coli as a Maltose-binding-protein chimera tagged at the Cterminus with the MycHis6 tag (MbpSic1 mycHis6 ) was purified as described (S7) . It was phosphorylated and ubiquitinated utilizing insect expressed kinase and SCF Cdc4 complexes as described (S8) . Ubiquitinated MbpSic1 mycHis6 was designated UbSic1 in the text.
Purification of 26S proteasomes
26S proteasomes were purified from S. cerevisiae cells expressing a Flag-tagged proteasomal subunit (PRE1) essentially as described (S9) . Briefly, lysates were immunoaffinity purified on anti-Flag resin in the presence of 2mM ATP and 5 mM MgCl 2 , and eluted with Flag peptide. 26S proteasomes were purified from rat liver as described (S10).
Degradation of UbSic1
Ubiquitinated Sic1 (~300 nM) was incubated with purified 26S proteasomes (~100 nM) at 30°C for 5 min (S9). The reaction tubes were transferred to ice and quenched with 5X Laemmli SDS sample buffer. Aliquots were resolved by SDS-PAGE, transferred to nitrocellulose, and immunoblotted with polyclonal anti-Sic1 antibody.
Deubiquitination of UbSic1
Purified 26S proteasomes were preincubated with 100 uM epoxomicin at 30°C for 45 min before addition of UbSic1 (S11). Reactions were processed as above.
Purification of Gst-Fusion Proteins
Recombinant proteins were purified as described (S12).
Binding of UbSic1 to 26S proteasomes
26S proteasomes were immunoprecipitated with anti-Flag resin from tagged and untagged control strains and incubated with 1 mM phenanthroline, 2.5 µM Ub-aldehyde, and 100 µM MG132 at 4°C for 45 min. (yielding a final intracellular concentration of 50-100 nM) and Protac (10µM) as previously described (S13).
Ornithine Decarboxylase Degradation Experiments
Assays of the degradation of 35 S -mODC were performed as described (S10) in a volume of 20 µl at 37 °C and contained: 50mM Tris-HCl pH7.5, 5 mM MgCl 2 , 1 mM ATP, 10 mM KCl, 10 % glycerol, an ATP regenerating buffer (2 mM DTT, 10 mM creatine phosphate, 1.6 mg/ml creatine kinase), 2 mg/ml BSA, 50 nM 
NMR studies
Synthesis of segmentally 15 N-labeled Ub 2 chains was performed as described in (S14). Ubiquitin monomers and C170S-E2 25K were expressed and purified as described in (S15 ubiquitin. The experiment in part (A) was repeated as described above, except that methylated ubiquitin was added to a concentration of 1 mg/ml. Extracts were supplemented with no additional ubiquitin ("no ubiquitin") or 1 mg/ml ubiquitin ("plus ubiquitin"), to compete with methylated ubiquitin. (C) An image of a sample assay plate from the screen. The arrow indicates a well that was considered a "hit" in the screen. value for the inhibitor, M equals the value in a mitotic extract lacking inhibitor, and I equals the value in an interphase extract. In testing known inhibitors, we noted that even potent inhibitors, such as roscovitine, required much higher concentrations in Xenopus extracts than in purified enzyme systems. For example, roscovitine exhibited an IC 50 of 30 µM in Xenopus extracts, whereas its reported IC50 against purified cyclin B1/cdc2 is 650 nM (S17). We believe this is due to the high concentration of lipid and protein (>30 mg/ml) in Xenopus extracts which may sequester compound. We also noted that MG132
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Page 22 and epoxomicin did not fully prevent loss of cyc-luc activity, even at high concentration (F). Assessment of proteins by western blotting, however, indicated that proteins are fully stabilized by higher concentrations of these inhibitors. We believe this discrepancy is due to proteasome-dependent unfolding and inactivation of the luciferase enzyme in the presence of 20S inhibitors. C10  IB  C5255908  NA  C1  IIA  C5271852  NA  C2  IIA  C5117023  901-47-3  C8  IIA  C145663  NA  C23  IIB  NSC14226 5429-79-8  C59  IIB  NSC306455 NA  C92  IIB  NSC665534 NA   Table S1 : Identification numbers for compounds reported in Table 1 . "ID#" refers to the identification number of the inhibitor obtained from the NCI (prefaced by NSC) or Chembridge (prefaced by C). CAS refers to the chemical abstract services number and is included where available; NA indicates that a CAS number was not available.
